

## Personal information



## Actual employment / Occupational field

### Senior Scientist in translational liver oncology

Italian Liver Foundation – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy

---

January 2012 –to present

**Senior Scientist – Italian Liver Foundation**  
Group Leader – Liver cancer Unit

Main activities and responsibilities

**May 2022 to present**

**Scientific Collaborator - unit coordinator**

Characterization of the serum proteome in subjects affected by Prader Willi syndrome with different degrees of fatty liver disease (PROTEOMARKER), 01C216; code CE:2022\_03\_15\_07 IRCCS Auxologico, MI

Main activities and responsibilities

experimental design, offering expertise in biomarker discovery and validation, support in the project management, analysis of data and production of scientific publications

**May 2022 to present**

**Scientific Collaborator - unit coordinator**

Characterization of the serum proteome in obese young people with different degrees of fatty liver disease (POSING), 01C217 ; code CE:2022\_03\_15\_08I RCCS Auxologico, MI

Main activities and responsibilities

experimental design, offering expertise in biomarker discovery and validation, support in the project management, analysis of data and production of scientific publications

**August 2021 to April 2023**

**Principal investigator and project coordinator**

**INTERREG ITA\_SLO 2014-2020 11CTE**, Cross-border biobanking model for the collection and management of biological samples for translational research studies and industrial research on the field of biomarkers discovery and validation

Main activities and responsibilities

Coordination and management, setting-up a crossborder biobank, defining SOPs

Name and address of employer

Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy

<b>January 2018 to December 2022</b>	<b>Collaborator– unit coordinator</b> Unrevealing the role of Ape1 in regulating tumor cell resistance to chemotherapy through miRNA processing in HCC and in NSCL. AIRC IG-19862
Main activities and responsibilities	Biomarker discovery, experimental molecular biology, identification of circulating miRNAs associated to SAPE1 levels, analysis of data and production of scientific publications
<b>July 2019 – August 2021</b>	<b>Collaborator– unit coordinator</b>
Occupation or position held	Working on the Gender-related response to Tyrosine Kinase-Inhibitor drugs in hepatocellular carcinoma (GReKIAH) project, funded by the National Drug Agency (AIFA) (study number TRS-2018-00001238 3.
Main activities and responsibilities	Coordinating research activities, experimental setting and management
Name and address of employer	Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy
Type of business or sector	Molecular cancer Medicine, Biomarker discovery
<b>May 2017 – April 2019</b>	<b>Principal investigator and project coordinator</b>
Occupation or position held	R&D project “SURFACE ENHANCED RAMAN MICRORNA PER LA DIAGNOSI E MANAGEMENT DEL CANCRO (SERMI4CANCER) – funded by POR-FESR 2014-2020 axis 1 activity 1.3 approved with DGR n4526 16/6/17.
Main activities and responsibilities	Project in collaboration with Hospitals, SME, Large enterprise and Universities. Development of a SERS-RAMAN based POC device for the detection of circulating miRNAs
Name and address of employer	Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy
Type of business or sector	Molecular cancer Medicine, Biotechnology, Research and Innovation, from bench to bedside and back
<b>March 2014 – January 2017</b>	<b>Senior researcher - Principal investigator</b>
Occupation or position held	R&D project “NETWORK FOR ELECTRONIC CLINICAL TRIAL ENVIRONMENT (NECTE)” – funded by PAR FSC 2007–2013 Attività 3.1.2: Bando per la realizzazione di progetti di ricerca e innovazione nell’ambito del Distretto tecnologico di biomedicina molecolare del Friuli Venezia Giulia approvato con DGR n°960/LAVFOR.ISTR/2014.
Main activities and responsibilities	Project in collaboration with Hospitals, SME, big companies and Universities. Circulating miRNAs profiles in Cancer, prognostic biomarkers – pilot study for the Electronic clinical trial record forOMIC data, clinical database management.
Name and address of employer	Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy
Type of business or sector	Molecular cancer Medicine, Biotechnology, Research and innovation
<b>January 2012 – March 2014</b>	<b>Post-Doc- Principal investigator</b>
Occupation or position held	R&D and prototyping project D.NAMICA “Platform for personalized molecular medicine – funded by POR FESR 2007-2013 Attività 1.1b: Bando per la realizzazione di progetti di ricerca industriale nel settore della biomedicina molecolare approvato con DGR n.2340 del 22 ottobre 2009.
Main activities and responsibilities	Project in collaboration with Hospitals, SME, Large companies and Universities. Circulating miRNAs profiles in Cancer, predictive and prognostic biomarkers – pilot study for the development of Electronic Clinical Records forOMIC data management, clinical database creation and management.
Name and address of employer	Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy
Type of business or sector	Molecular cancer Medicine, Biotechnology, Research and innovation.

<b>January 2009 – December 2011</b>	<b>Research internship</b>
Occupation or position held	Ph.D. student
Main activities and responsibilities	Study focused on ABC transporters, cancer molecular biology and gene therapy.
Name and address of employer	Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy
Type of business or sector	Molecular and cellular biology
<b>September 2007 – October 2008</b>	<b>Research internship</b>
Main activities and responsibilities	Research on the polycomb group gene in <i>Coffea</i> .
Name and address of employer	Università degli studi di Trieste – Life Sciences Department
Type of business or sector	Plant genetics and molecular biology
<b>January 2007 – February 2007</b>	<b>Working experience</b>
Main activities and responsibilities	Testing new ELISA kit for serological antiphospholipid antibodies
Name and address of employer	TECHNOGENETICS s.r.l Viale Casiraghi 471, 20099 Sesto San Giovanni (MI)
Type of business or sector	Clinical biochemistry
<b>February 2006 – July 2006</b>	<b>Research internship</b>
Main activities and responsibilities	Circulating thrombosis risk factors in young obese
Name and address of employer	Università degli studi di Trieste - IRCCS Burlo Garofolo Hospital, Trieste
Type of business or sector	Clinical biochemistry

## Teaching activities

<b>March 2022-Jun 2022</b>	Teaching activity, cellular Biology, laboratory course, University of Trieste, Bachelor Degree Program SM51 - BIOLOGICAL SCIENCES AND TECHNOLOGIES. MIUR: L-2 / L-13. Call 164. 20/01/2022
<b>March 2021-Jun 2021</b>	Teaching activity, cellular Biology, laboratory course, University of Trieste, Bachelor Degree Program SM51 - BIOLOGICAL SCIENCES AND TECHNOLOGIES. MIUR: L-2 / L-13. Call 160. 20/01/2021
<b>2-25, May 2019</b>	Visiting Professor at Universitas Hasanuddin, Makassar, Sulawesi
<b>20-21, September 2018</b>	CME Training Course for physicians Preceptorship in translational hepatology

**20, May 2014** CME Training Course for physicians and Biology laboratory personnel  
Verso la medicina personalizzata in FVG: risultati ed esperienze del progetto D.NAMICA

**4, May 2007** CME Training Course for physicians and Biology laboratory personnel  
Obesità infantile, una patologia emergente: dall'evidenza clinica alla medicina di Laboratorio.

## Education and training

### January 2009 – December 2011

Title of qualification awarded **Ph.D. in molecular Medicine**  
Name and type of organisation providing education and training Università degli studi di Trieste - Fondazione Italiana Fegato – ONLUS, Area Science Park, ss14 Km 163,5, 34149 Basovizza, TS, Italy

### October 2006- October 2008

Title of qualification awarded **Master Degree in Functional Genomis**, Score 110/110 Cum Laude  
Name and type of organisation providing education and training Università degli studi di Trieste

### October 2001- July 2006

Title of qualification awarded **Bachelor Degree in Biology and Molecular and Cellular Technologies**, Score 110/110 Cum Laude  
Name and type of organisation providing education and training Università degli studi di Trieste

## Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment  
*European level* (\*)

**English**

**Spanish**

**French**

**Indonesian**

### Understanding

Listening	Reading
good	good
good	good
basic	basic
limited	limited

### Speaking

Spoken interaction	Spoken production
good	good
good	discrete
basic	
basic	limited

### Writing

good
basic
limited
limited

(\*) *Common European Framework of Reference for Languages*

Social skills and competences

Problem solving skills, self management & professionalism, leadership, cooperative, mentoring, hones and ethical behavior, sense of multiculturalism, adaptability, work better in team, sharing expertise and knowledge, friendly with people

Organisational skills and competences

Expert in defining and establishing new research projects  
 Competences in research planning (short and long term), including budgeting.  
 Competences in writing research proposals (National and international grants)  
 Competences as PI or Project coordinator.  
 Able to define SOPs  
 skilled in organizing and establishing new research laboratories  
 Networking expertise (companies, Universities, research institutions)  
 Teaching skills, in university classes, professional courses.  
 Able to train post-doctoral fellow, PhD students and master degree students.  
 Able to organize tasks in a team situation and meet dead lines  
 Always stimulated by new research challenges  
 Interested in learning new techniques, procedures, languages.

Technical skills and competences

Bioinformatic Skills, Silencing, PCR related techniques (RT-PCR, 3'RACE, 5'RACE, Nested PCR), Electrophoretic techniques, Cloning in bacteria, ELISA, Total, nuclear, and Membrane protein isolation and analysis, RNA isolation and analysis (from plants, human cell cultures and tissues), small RNAs isolation and analysis, Real Time PCR, SDS-Page Western blot, Flow Cytometry, Cell culture, human primary cell culture, PBMC isolation, microscopy, fluorescence microscopy, in vitro cell toxicity assays, miRNA profiling, gene array, miRNA qRT-PCR, gene reporter assays, Protein/RNA pull down assay, immunofluorescence and IHC, enzymatic assays, TRAP assay, Telomere length assay, cell-based functional assays (i.e apoptosis, pyroptosis, cell cycle, cell migration, cell invasion), hand on cell sorting, metabolomics, alphasia.

Computer skills and competences	<b>European Computer Driving Licence</b>				
	tools	good	discrete	basic	limited
Microsoft Word package	x				
Microsoft Outlook	x				
Statistical analysis (NCSS)	x				
Statistical computing (R)				x	
Data processing (Trancriptome analysis console, Mev4, genesis, R)	x		x		
Online databases (NCBI, EBI, miRBase, Mirtarbase, GEO, Gene Ontology, and others)	x		x		
Gene enrichment (Gorilla, Gene Ontology, Genecodis)	x				
Wordpress				x	

Driving licence Italy (B)

**Other activities and hobbies** Volleyball trainer (B-D league- Italy), sports, painting

## PUBLICATIONS

### Abstracts and oral presentations

- NOVEMBER 2024 **Devis Pascut.** Le biobanche: una risorsa inestimabile per il progresso della ricerca biomedica. Biopreservación de Recursos Biológicos y su aplicación en la gestión y manejo de Biobancos y Centros de Recursos Biológicos. November 15, 2024, Rosario, Argentina (**oral presentation**)
- OCTOBER 2024 Grisetti L, Saponaro AA, Sukowati C, Bonazza D, Giacomello E, Tarchi P, Crocè LS, Palmisano S, Anfuso B, Tiribelli C, **Pascut D.** Relationship between Aurora Kinase A and Programmed Death-Ligand 1 Expression in Hepatocellular Carcinoma: The Regulatory Role of the Kinase in Immune Checkpoint Modulation. ILCA 2024 18<sup>th</sup> Annual Conference a Toronto, October 17-19, 2024 (**poster presentation**)
- Devis Pascut.** L'Intelligenza Artificiale in epatologia: esperienze del progetto genIA. National annual conference SISQT (Società Italiana per la sicurezza e la qualità nei trapianti), July 4-6, 2024, L'Aquila, Italy (**oral presentation**)
- SEPTEMBER 2024 **Devis pascut.** Enhancing Translational Research and Innovation through Biobanking: Insights from the C3B Project. New Trends on Sensing-Monitoring-Telediagnosis for Life Sciences – NT SMT–LS 2024, Braşov, Romania, September 20-22, 2024 (**oral presentation**)
- JUNE 2024 Grisetti L, Saponaro AA, Sukowati CHC, Bonazza D, Giacomello E, Tarchi P, Crocè LS, Palmisano S, Rosso N, Giraudi PJ, Anfuso B, Tiribelli C, **Pascut D.** Aurora Kinase A and Programmed Death-Ligand 1: Expression dynamics in hepatocellular carcinoma development and the regulatory role of the kinase in immune checkpoint modulation. EASL Congress, June 5-8, 2024, Milano, Italy 2024 (**poster presentation**)
- APRIL 2024 **Devis Pascut.** BIOBANKS TO BOOST RESEARCH AND HEALTHCARE, The UP System Biobank Committee and the Philippine Genome Center Biobank Core. April 8, 2024, Manila (**oral presentation**)
- MARCH 2024 Inah Marie C. Aquino, Leslie Michelle M. Dalmacio, Claudio Tiribelli, **Devis Pascut.** Investigation on the Tumor suppressor role of miR-3185 in Hepatocellular Carcinoma. 33<sup>rd</sup> APASL annual meeting, Kyoto, Japan on March 27-31, 2024 (**poster presentation**)
- MARCH 2024 Deciphering the Novel Functions of Aurora Kinase A in Chronic Liver Disease. Clarissa Garcia, Luca Grisetti, Loraine Kay Cabral, Caecilia Sukowati, Paola Tarchi, Deborah Bonazza, Emiliana Giacomello, Claudio Tiribelli, **Devis Pascut.** 33<sup>rd</sup> APASL annual meeting, Kyoto, Japan on March 27-31, 2024 (**poster presentation**)
- FEBRUARY 2024 Clarissa Garcia, Luca Grisetti, Caecilia Sukowati, Paola Tarchi, Deborah Bonazza, Emiliana Giacomello, Lory S. Crocè, Claudio Tiribelli, **Devis Pascut.** The Potential Modulatory Role of Aurora Kinase A on Yes-associated protein and Glycogen Synthase Kinase 3-beta in Advanced Chronic Liver Disease. EASL Liver Cancer Summit, 22-24 February, Rotterdam, Netherlands (**poster presentation**)
- JANUARY 2024 **Devis Pascut.** New insights in liver cancer. Seminar at BRIN – Eijkman Institute. January 29, 2024, Jakarta, Indonesia (**oral presentation**)
- JANUARY 2024 **Devis Pascut.** Redefining the global challenge of liver cancer: Personalized treatment breakthroughs and innovations in technology. CATALYST accelerate to a dynamic and sustainable future through innovations in life sciences and business. **Ancestral symposium, at I3L university** January 13, 2024, Jakarta, Indonesia (**oral presentation**)
- NOVEMBER 2023 **Devis Pascut.** How translational Research hepatology unlock future healthcare: Integrating basic science, biobanking and AI innovations. International conference and molecular biology workshop, November 27, 2024, Makassar, **Indonesia (oral presentation)**
- SEPTEMBER 2023 Luca Grisetti, Anna Alessia Saponaro, Caecilia H. C. Sukowati, Paola Tarchi, Lory Saveria Crocè, Silvia Palmisano, Natalia Rosso, Pablo J. Giraudi, Beatrice Anfuso, Claudio Tiribelli, **Devis Pascut.** The Expression of Aurora Kinase A and its potential role as a regulator of Programmed Death-Ligand 1 in Hepatocellular Carcinoma: Implications for Immunotherapy and Immune Checkpoint Regulation in Hepatocarcinogenesis. AISF Monothematic Conference 2023 “Liver oncology: from basic science to liver transplantation”, Padova, Italy, 28-29 September 2023 (**Poster presentation**)
- SEPTEMBER 2023 Luca Grisetti, Anna Alessia Saponaro, Caecilia H. C. Sukowati, Beatrice Anfuso, Paola Tarchi, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut.** The expression of Aurora kinase A in hepatocarcinogenesis and its potential role in Programmed Death–Ligand 1 regulation. ILCA annual Conference, 7-9 September 2023, Amsterdam, Netherland (**Poster presentation**)
- JUNE 2023 **Devis Pascut,** Diego Sardon. Artificial intelligence and health data management. A cup of Science 2023. Trieste, Italy, 22 June 2023 (**Oral presentation**)

- APRIL 2023 John Paul Llido, Emanuela Fioriti, **Devis Pascut**, Mauro Giuffrè, Cristina Bottin, Fabrizio Zanconati, Claudio Tiribelli, Silvia Gazzin. Regional and developmental perturbation of the central nervous system (CNS) in hyperbilirubinemic rats. The Brain Conferences, Rungstedgaard, Denmark, 23-26 April, 2023 (**Poster Presentation**).
- APRIL 2023 Luca Grisetti, Anna Alessia Saponaro, Caecilia Sukowati, Paola Tarchi, Saveria Lory Croce', Claudio Tiribelli, **Devis Pascut**. The role of Aurora kinase A in hepatocellular carcinoma: possible regulation of Programmed death-ligand 1 EASL Liver Cancer Summit, 20-22 April, Estoril, Portugal (**Poster Presentation**).
- OCTOBER 2022 **Devis Pascut**. Cross-border pilot actions to boost innovation in the health system through data sharing"20th EUROPEAN WEEK OF REGIONS AND CITIES, October 12, 2022, online workshop (**Oral presentation**)
- SEPTEMBER 2022 **Devis Pascut**. Il progetto Interreg C3B: una cooperazione transfrontaliera per costruire una rete di biobanche nell'Area di Programma. Interreg projekt C3B: čezmejno sodelovanje za vzpostavitev mreže biobank v programskem območju. Strokovno srečanje projekta Čezmejna platforma za učinkovito upravljanje biobank, Meeting professionale del progetto Piattaforma transfrontaliera per una gestione efficiente delle biobanche. September 29, 2022, Ljubljanski grad, Hribarjeva dvorana (**Oral Presentation**)
- SEPTEMBER 2022 **Devis Pascut**. La rete transfrontaliera delle biobanche epatologiche: Il Progetto C3B Interreg. Le Biobanche per la ricerca scientifica: il polo udinese , esperienze in Friuli e i modelli europei di successo. September 20, 2022, Udine (**Oral Presentation**)
- SEPTEMBER 2022 Grisetti Luca, **Devis Pascut**, Caecilia H. Sukowati, Claudio Tiribelli. Exploring the effects of Aurora Kinase A inhibition in liver cancer: A possible link to PD-L1 regulation. 16<sup>th</sup> ILCA Annual Conference, 1-4 September 2022, Madrid (**Poster Presentation**).
- SEPTEMBER 2022 Aquino Inah Marie, Leslie Michelle M. Dalmacio, Claudio Tiribelli, **Devis Pascut**. The tumor suppressor roles of miR-3185 in hepatocellular carcinoma. 16<sup>th</sup> ILCA Annual Conference, 1-4 September 2022, Madrid (**Poster Presentation**).
- FEBRUARY 2020 **Devis Pascut**, Muhammad Yogi Pratama, Luisa Cavalletto, Chiara Andolfi, Silvia Bresolin, Luca Trentin, Giuseppe Basso, Giorgio Bedogni, Claudio Tiribelli, Liliانا Chemello. Circulating Small-RNAs signatures evidenced a susceptibility to HCC occurrence in DAA treated patients. EASL Liver Cancer Summit, 06-08 February, Prague. (**Poster Presentation**).
- Muhammad Yogi Pratama, Alessia Visintin, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut**. Circulating miR-4454 as a predictor of therapy response and disease free survival in hepatocellular carcinoma. EASL Liver Cancer Summit, 06-08 February, Prague. (**Poster Presentation**).
- JULY 2019 **Devis Pascut**, SERMI4Cancer, Surface enhanced Raman microRNA per la diagnosi e management del cancro. Meeting, nuove frontiere nell'analisi oncologica: sviluppo di innovative sistemi di diagnosi e management del cancro. Trieste 9<sup>th</sup> July 2019. (**Oral Presentation and Chairman**)
- MAY 2019 **Devis Pascut**, Technique to write a review and international collaboration. Department of clinical pathology, faculty of medicine, Universitas Hasanuddin. 24<sup>th</sup> May 2019, (**Oral Presentation**)
- APRIL 2019 **Devis Pascut**, Francesca Gilardi, Muhammad Yogi, Pratama Riccardo Patti, Lory Saveria Crocè, Claudio Tiribelli. Blood based Weighted gene co-expression network analysis (WGCNA) identifies miRNA prognostic biomarkers for HCC. EASL International Liver Congress 2019, Vienna, 10-14 April 2019. (**Poster Presentation**).
- APRIL 2019 Muhammad Yogi Pratama, Alessia Visintin, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut**. Circulating miR-4492 as a Biomarker to Predict Therapy Response and Disease Free Survival in Hepatocellular. EASL International Liver Congress 2019, Vienna, 10-14 April 2019. (**Poster Presentation**).
- FEBRUARY 2019 Muhammad Yogi Pratama, Alessia Visintin, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut** Circulating miR-3185 as a Predictive marker for Overall Survival in Patients with Hepatocellular Carcinoma. Annual Meeting AISF 2019, Rome 20-21 February 2019. (**Poster Presentation**).

- FEBRUARY 2019 **Devis Pascut**, Alois Bonifacio, Alessia Visintin, Alessia Di Silvestre, Elisa Mitri, Lory Saveria Crocè, Claudio Tiribelli. Surface enhanced Raman spectroscopy as a diagnostic tool for circulating miRNA detection in HCC: the SERMI4cancer project. Annual Meeting AISF 2019, Rome 20-21 February 2019. **(Poster Presentation)**.
- FEBRUARY 2019 **Devis Pascut**, Muhammad Yogi Pratama, Francesca Gilardi, Riccardo Patti, Lory Saveria Crocè, Claudio Tiribelli. Weighted gene co-expression network analysis of circulating miRNAs as a tool to discover prognostic biomarkers for Hepatocellular Carcinoma. Annual Meeting AISF 2019, Rome 20-21 February 2019. **(Poster Presentation)**.
- FEBRUARY 2019 Muhammad Yogi Pratama, Alessia Visintin, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut**. Circulating miR-4507 as a novel prognostic biomarker in Hepatocellular Carcinoma. EASL HCC summit 2019, Lisbon 14-16 February 2019. **(Poster Presentation)**.
- FEBRUARY 2019 **Devis Pascut**, Francesca Gilardi, Muhammad Yogi Pratama, Riccardo Patti, Lory Saveria Crocè, Claudio Tiribelli. Changes in the circulating miRNome profiles after therapy identify miRNA predictive biomarkers for HCC recurrence. EASL HCC summit 2019, Lisbon 14-16 February 2019, **(Poster Presentation)**.
- SEPTEMBER 2018 Muhammad Yogi Pratama, Francesca Gilardi, Helena Krmac, Raffaella Calligaris, Ricardo Patti, Lory Crocè, Claudio Tiribelli, **Devis Pascut**. IDENTIFICATION OF SMALL NON-CODING RNAS (SNCRNAS) SIGNATURE FROM BLOOD AND SERUM TO PREDICT DISEASE FREE SURVIVAL IN HEPATOCELLULAR CARCINOMA. ILCA's twelve Annual Conference, London-14-16 September **(Poster Presentation)**.
- APRIL 2018 C. Sukowati, R. Patti, **D. Pascut**, R.B. Ladju, P. Tarchi, N. Zanotta, M. Comar, C. Tiribelli, L. Crocè. A new insight on the stem cell growth factor beta as a strong predictor of therapy response in hepatocellular carcinoma. The International Liver Congress, April 11-15 2018 Barcelona, Paris. **(poster presentation)**
- NOVEMBER 2016 P. Popović, C. Tiribelli, **D. Pascut**. The role of mir-124 in the adaptive mechanisms leading to multidrug resistance in HCC. Gastro 2016: EGHS-WGO International Congress, 17-19 November 2016 Abu Dhabi, United Arab Emirates **(Poster Presentation)**.
- OCTOBER 2016 Changes in circulating microRNA after treatment: microRNA signatures to predict therapy response and disease free survival in hepatocellular carcinoma patients. **Devis Pascut**, Helena Krmac, Nicolò Mezzina, Riccardo Patti, Danilo Licastro, Simeone Dal Monego, Cristiana Abazia, Luisa Petracchia, Flora Masutti, Saveria L. Crocè, Raffaella Calligaris, Claudio Tiribelli. UEG Week Vienna - October 15-19, 2016. **(oral presentation)**
- APRIL 2016 P. Popović, C. Tiribelli, **D. Pascut**. Adaptive mechanisms leading to multidrug resistance in Hepatocellular carcinoma. The International Liver Congress, April 13-17 2016 Barcelona, Spain. **(poster presentation)**
- APRIL 2016 I. Martinozzi, N. Rosso, C. Tiribelli, **D. Pascut**. Molecular networks in hepatocellular carcinoma: the extratelomeric effects of telomerase. The International Liver Congress, April 13-17 2016 Barcelona, Spain. **(poster presentation)**
- FEBRUARY 2016 **Devis Pascut**, Helena Krmac, Nicolò Mezzina, Riccardo Patti, Danilo Licastro, Simeone Dal Monego, Cristiana Abazia, Luisa Petracchia, Flora Masutti, S. L. Crocè, R. Calligaris, C. Tiribelli. Circulating microRNA in hepatocellular carcinoma as prognostic biomarkers. 49th Annual Meeting of the Italian Association for the Study of the Liver, Rome, February 18th-19th, 2016. **(poster presentation)**
- FEBRUARY 2016 I. Martinozzi, N. Rosso, C. Tiribelli, **D. Pascut**. The telomerase extratelomeric effects in HCC: Molecular targeting to impair tumoral networks in HCC. 49th Annual Meeting of the Italian Association for the Study of the Liver, Rome, February 18th-19th, 2016. **(poster presentation)**
- FEBRUARY 2016 P. Popović, C. Tiribelli, **D. Pascut**. The Role of mir-124 and Aurora kinase-A in the multidrug resistance in HCC. 49th Annual Meeting of the Italian Association for the Study of the Liver, Rome, February 18th-19th, 2016. **(oral presentation)**
- JULY 2015 **Devis Pascut**, Helena Krmac, Nicolò Mezzina, Riccardo Patti, Danilo Licastro, Simeone Dal Monego, Cristiana Abazia, Luisa Petracchia, Flora Masutti, Claudio Tiribelli, Raffaella Calligaris, Saveria L. Crocè. HEPATOCELLULAR CARCINOMA CIRCULATING MICRORNA PROFILING. 4th Biomarkers in Diagnostics Conference, October 7-8 2015, Berlin, Germany **(poster presentation)**
- JULY 2015 **D. Pascut**, R. Patti, G. Bedogni, C. Tiribelli. miRNA target enrichment network analysis in Hepatocellular carcinoma. 40th FEBS Congress – The Biochemical Basis of Life, Berlin, July, 4–9 2015. **(Oral presentation)**

- JULY 2015 **D. Pascut**, R. Patti, G. Bedogni C. Tiribelli. miRNA target enrichment network analysis in Hepatocellular carcinoma. 40th FEBS Congress – The Biochemical Basis of Life, Berlin, July, 4–9 2015.(**poster presentation**)
- FEBRUARY 2015 C. H.C. Sukowati, B. Anfuso, **D. Pascut**, R. Patti, N. Mezzina, P. Tarchi, S.L. Crocè, C. Tiribelli. Distribution of stem cells and cancer stem cells markers in liver pathologies and their indication to the response of therapy. 48th Annual Meeting of the Italian Association for the Study of the Liver". Rome, February 19<sup>th</sup>-20<sup>th</sup>, 2015.(**poster presentation**)
- FEBRUARY 2015 R. Patti, N. Mezzina, F. Masutti, C. Abazia, V. Lanzillotti, **D. Pascut**, C. H.C. Sukowati, F. Pozzi Muceli, C. Tiribelli, S.L. Crocè. TACE with cone beam computed tomography is more effective than traditional technique in BCLC A HCC patients ineligibile to surgery. 48th Annual Meeting of the Italian Association for the Study of the Liver". Rome, February 19<sup>th</sup>-20<sup>th</sup>, 2015.(**poster presentation**)
- FEBRUARY 2015 **D. Pascut**, R. Patti, N.Mezzina, C. Abazia, F. Masutti, S.L. Crocè, C. Tiribelli. Mir-106b for HCC Patient management after therapy. 48th Annual Meeting of the Italian Association for the Study of the Liver". Rome, February 19<sup>th</sup>-20<sup>th</sup>, 2015. (**poster presentation**)
- MAY, 2014 D.Pascut. A00R\_01183 – Verso la medicina personalizzata in Friuli Venezia Giulia: risultati ed esperienze del progetto D.NAMICA. MicroRNA come marcatori nel carcinoma epatico: possibili applicazioni in campo oncologico (**Oral Presentation**).
- FEBRUARY 2014 Igino Rigato , Riccardo Patti , Manuela Pastoricchio, Flora Masutti, **Devis Pascut**, Valentina Lanzilotti, Fabio Pozzi, Cristiana Abazia, Claudio Tiribelli, Lory S. Croce'. Management of intermediate stage of HCC: A comparison between conventional and drug-eluting beads tace. "EASL HCC summit: Molecular Pathogenesis & Translational Research in Liver Cancer", Geneva (**poster presentation**).
- SEPTEMBER 2012 **Devis Pascut**, Natalia Rosso, Claudio Tiribelli. Targeting telomerase reverse transcriptase: A molecular approach for gene therapy in HCC. "IUBMB & FEBS congress: From single molecules to systems biology", Sevilla, September 4<sup>th</sup>-9<sup>th</sup>, (**poster presentation**)
- JUNE, 2011 N. Rosso, **D. Pascut**, C. Tiribelli. Molecular events in the development of Doxorubicin Resistant Hepatic cell lines. 36th FEBS Congress, Biochemistry for Tomorrow's Medicine June, 25-30 2011.(**poster presentation**)
- MAY, 2011 N. Rosso, **D. Pascut**, C. Tiribelli. Establishment of Doxorubicin-Resistant Hepatic cell lines. SIBBM seventh annual Seminar "Frontiers in Molecular Biology", Trieste (**Poster Presentation**).
- MAY, 2011 **D. Pascut**, N. Rosso, C. Tiribelli. Exploring Telomerase silencing effects in HCC. SIBBM seventh annual Seminar "Frontiers in Molecular Biology", Trieste (**Poster Presentation**).
- SEPTEMBER, 2009 C. H. C. Sukowati, N. Rosso, **D. Pascut**, C. Tiribelli. The BCRP expression and drug resistance in hepatocellular carcinoma. ILCA's third Annual Conference, Milano (**Poster Presentation**).
- SEPTEMBER, 2009 **Pascut**, N. Rosso, C. H. C. Sukowati, C. Tiribelli. Modulation of ABC transporters expression and multidrug resistance in HCC. ILCA's third Annual Conference, Milano (**Poster Presentation**).
- OCTOBER, 2007 M. Donato, **D. Pascut**, S. Parco, T. Princi, G. Tamaro. Markers emocoagulativi di rischio trombotico nel bambino obeso. 39° Congresso Nazionale della Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (**Poster Presentation**).
- MAY, 2007 S. Parco, **D. Pascut**, G. Tamaro. Obesità infantile, una patologia emergente: dall'evidenza clinica alla medicina di laboratorio. "Markers emocoagulativi di rischio coronario nel bambino obeso". Trieste (**Oral Presentation**).

### Publications in indexed journals

- NOVEMBER 2024 Clarissa Joy C. Garcia, Luca Grisetti, Claudio Tiribelli and **Devis Pascut**. The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges. *Life* 2024, 14(11), 1430; <https://doi.org/10.3390/life14111430>
- SEPTEMBER 2024 **Pascut D**, Giraudi PJ, Banfi C, Ghilardi S, Tiribelli C, Bondesan A, Caroli D, Grugni G, Sartorio A. Characterization of Circulating Protein Profiles in Individuals with Prader-Willi Syndrome and Individuals with Non-Syndromic Obesity. *J Clin Med*. 2024 Sep 25;13(19):5697. doi: 10.3390/jcm13195697.
- JULY 2014 **Pascut D**, Giraudi PJ, Banfi C, Ghilardi S, Tiribelli C, Bondesan A, Caroli D, Minocci A, Sartorio A. Serum proteome signatures associated with liver steatosis in adolescents with obesity. *J Endocrinol Invest*. 2024 Jul 17. doi: 10.1007/s40618-024-02419-x

- APRIL 2024 Grisetti L, Garcia CJC, Saponaro AA, Tiribelli C, **Pascut D**. The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer. *Cell Prolif*. 2024 Apr 8:e13641. doi: 10.1111/cpr.13641. Online ahead of print. PMID: 38590119
- MARCH 2024 Aquino IMC, **Pascut D**. Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care. *Ann Hepatol*. 2024 Mar-Apr;29(2):101176. doi: 10.1016/j.aohep.2023.101176. Epub 2023 Nov 14. PMID: 37972709
- NOVEMBER 2023 **Pascut D**, Giraudi PJ, Banfi C, Ghilardi S, Tiribelli C, Bondesan A, Caroli D, Minocci A, Grugni G, Sartorio A. Proteome profiling identifies circulating biomarkers associated with hepatic steatosis in subjects with Prader-Willi syndrome. *Front Endocrinol (Lausanne)*. 2023 Nov 15;14:1254778. doi: 10.3389/fendo.2023.1254778. eCollection 2023.
- ULY 2023 Giovanna Mangiapane\*, **Devis Pascut\***, Emiliano Dalla, Giulia Antoniali, Monica Degrassi, Lory Saveria Crocè, Veronica De Sanctis, Silvano Piazza, Giulia Canarutto, Claudio Tiribelli, Gianluca tell. Clinical Significance of Apurinic/Apyrimidinic Endodeoxyribonuclease 1 and MicroRNA Axis in Hepatocellular Carcinoma. *Journal of Clinical and Translational Hepatology* 2023, doi: 10.14218/JCTH.2022.00179
- JUNE 2023 Llido JP, Fioriti E, **Pascut D**, Giuffrè M, Bottin C, Zanconati F, Tiribelli C, Gazzin S. Bilirubin-Induced Transcriptomic Imprinting in Neonatal Hyperbilirubinemia. *Biology (Basel)*. 2023 Jun 8;12(6):834. doi: 10.3390/biology12060834.
- DECEMBER 2022 Grisetti L, Võ NVT, Nguyễn NNQ, Crocè LS, Visintin A, Tiribelli C, **Pascut D**. MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma. *Technol Cancer Res Treat*. 2022 Jan-Dec;21:15330338221132924.
- MAY 2022 Cabral LKD, Grisetti L, Pratama MY, Tiribelli C, **Pascut D**. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. *Cancers (Basel)*. 2022 May 30;14(11):2700.
- MAY 2022 Andolfi C, Tiribelli C, **Pascut D**. Recent Hints on the Dual Role of Discs Large MAGUK Scaffold Protein 5 in Cancers and in Hepatocellular Carcinoma. *Front Biosci (Landmark Ed)*. 2022 May 20;27(5):164.
- FEBRUARY 2022 Bozzato AM, Martingano P, Pozzi Mucelli RA, Cavallaro MFM, Cesarotto M, Marcello C, Tiribelli C, **Pascut D**, Pizzolato R, Pozzi Mucelli F, Giuffrè M, Crocè LS, Cova MA. MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. *Diagnostics (Basel)*. 2022 Feb 1;12(2):374.
- MAY 2021 **Pascut D**, Hoang M, Nguyen NNQ, Pratama MY, Tiribelli C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. *Cancers (Basel)*. 2021 May 19;13(10):2485. doi: 10.3390/cancers13102485.
- MARCH 2021 Masadah R, Rauf S, Pratama MY, Tiribelli C, **Pascut D**. The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer. *Cancers (Basel)*. 2021 Mar 9;13(5):1168. doi: 10.3390/cancers13051168
- JANUARY 2021 Sukowati CHC, Cabral LKD, Tiribelli C, **Pascut D**. Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. *Biomedicines*. 2021 Jan 19;9(1):90. Doi: 10.3390/biomedicines9010090.
- DECEMBER 2020 Gurian E, Di Silvestre A, Mitri E, **Pascut D**, Tiribelli C, Giuffrè M, Crocè LS, Sergo V, Bonifacio A. Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients. *Anal Bioanal Chem*. 2020 Dec 8. Doi: 10.1007/s00216-020-03093-7
- NOVEMBER 2020 **Pascut D**, Pratama MY, Gilardi F, Giuffrè M, Crocè LS, Tiribelli C. Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients. *Sci Rep*. 2020 Nov 3;10(1):18967. Doi: 10.1038/s41598-020-75945-2
- SEPTEMBER 2020 Pratama MY, Visintin A, Crocè LS, Tiribelli C, **Pascut D**. Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma. *Cancers (Basel)*. 2020 Sep 29;12(10):2810. Doi: 10.3390/cancers12102810
- JUNE 2020 **Pascut D**, Pratama MY, Tiribelli C. HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance. *Hepat Oncol*. 2020 Jun 22;7(2):HEP21. doi: 10.2217/hep-2020-0010.

- APRIL 2020 **Pascut D, Pratama MY, , Tamini S, Minocci A, Tiribelli C, Grugni G, Sartorio A** Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader-Willi Syndrome and Non-Syndromic Obesity. *J Clin Med.* 2020 Apr 14;9(4):1123. Doi: 10.3390/jcm9041123
- MARCH 2020 **Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C.**The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and their Clinical Implications. *Cancers (Basel).* 2020 Mar 29;12(4):823. doi: 10.3390/cancers12040823.
- FEBRUARY 2020 Pratama MY, Cavalletto L, Tiribelli C, Chemello L, **Pascut D.** Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma. *Sci Rep.* 2020 Feb 21;10(1):3128. Doi: 10.1038/s41598-020-59682-0
- NOVEMBER 2019 **Pascut D, Cavalletto L, Pratama MY, Bresolin S, Trentin L, Basso G, Bedogni G, Tiribelli C, Chemello L.** Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. *Cancers.* 2019; 11;11(11). pii: E1773. Doi: 10.3390/cancers11111773
- SEPTEMBER 2019 Pratama MY, **Pascut D, Massi MN, Tiribelli C.** The role of microRNA in the resistance to treatment of hepatocellular carcinoma. *Ann. Transl Med.* 2019, 7(20):577. Doi: 10.21037/atm.2019.09.142.
- MAY 2019 **Pascut D, Krmac H, Gilardi F, Patti R, Calligaris R, Crocè LS, Tiribelli C.** A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients. *Sci Rep.* 2019 Jun 4;9(1):8265. doi: 10.1038/s41598-019-44580-x.
- APRIL 2019 Muhammad Yogi Pratama, Alessia Visintin, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut.** Circulating miR-4492 as a Biomarker to Predict Therapy Response and Disease Free Survival in Hepatocellular. *EASL International Liver Congress 2019, Vienna, 10-14 April 2019. J.Hepatology 2019 Vol.70, 1S e375. doi.org/10.1016/S0168-8278(19)30203-X*
- APRIL 2019 **Devis Pascut, Francesca Gilardi, Muhammad Yogi, Pratama Riccardo Patti, Lory Saveria Crocè, Claudio Tiribelli.** Blood based Weighted gene co-expression network analysis (WGCNA) identifies miRNA prognostic biomarkers for HCC. *EASL International Liver Congress 2019, Vienna, 10-14 April 2019. J.Hepatology 2019 Vol.70, 1S e373. doi.org/10.1016/S0168-8278(19)30203-X*
- 2019 Muhammad Yogi Pratama, Alessia Visintin, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, **Devis Pascut** Circulating miR-3185 as a Predictive marker for Overall Survival in Patients with Hepatocellular Carcinoma. *Digestive and Liver Disease 51 (2019) e18–e42. doi.org/10.1016/j.dld.2018.11.103*
- 2019 **Devis Pascut, Alois Bonifacio, Alessia Visintin, Alessia Di Silvestre, Elisa Mitri, Lory Saveria Crocè, Claudio Tiribelli.** Surface enhanced Raman spectroscopy as a diagnostic tool for circulating miRNA detection in HCC: the SERMI4cancer project. *Digestive and Liver Disease 51 (2019) e18–e42. doi.org/10.1016/j.dld.2018.11.110*
- 2019 **Devis Pascut, Muhammad Yogi Pratama, Francesca Gilardi, Riccardo Patti, Lory Saveria Crocè, Claudio Tiribelli.** Weighted gene co-expression network analysis of circulating miRNAs as a tool to discover prognostic biomarkers for Hepatocellular Carcinoma. *Digestive and Liver Disease 51 (2019) e18–e42. doi.org/10.1016/j.dld.2018.11.096*
- 2019 **Pascut D, Sukowati C, Antoniali G, Mangiapane G, Burra S, Mascaretti LG, Buonocore MR, Crocè LS, Tiribelli C, Tell G.** Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. *Oncotarget, 2019,10:383-394. Doi: 10.18632/oncotarget.26555. eCollection 2019 Jan 8.*
- 2018 **Pascut D, Tamini S, Bresolin S, Giraudi P, Basso G, Minocci A, Tiribelli C, Grugni G, Sartorio A.** Differences in circulating microRNA signature in Prader-Willi syndrome and non-syndromic obesity. *Endocr Connect.* 2018 Dec 1;7(12):1262-1274. doi: 10.1530/EC-18-0329.
- 2018 Sukowati CHC, Patti R, **Pascut D, Ladju RB, Tarchi P, Zanotta N, Comar M, Tiribelli C, Crocè LS.** Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma. *Biomed Res Int.* 2018 Aug 30;2018:6435482. doi: 10.1155/2018/6435482. eCollection 2018.
- 2018 C. Sukowati, R. Patti, **D. Pascut, R.B. Ladju, P. Tarchi, N. Zanotta, M. Comar, C. Tiribelli, L. Crocè.**A new insight on the stem cell growth factor beta as a strong predictor of therapy response in hepatocellular carcinoma. *J.Hepatology 2018 Volu 68, S1, S685–S686. doi.org/10.1016/S0168-8278(18)31629-5*

- 2017 Ladju RB, **Pascut D**, Massi MN, Tiribelli C, Sukowati CHC. Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. *Oncotarget*. 2017 Dec 16;9(2):2951-2961. doi: 10.18632/oncotarget.24572. eCollection 2018 Feb 27
- 2016 **Devis Pascut**, Helena Krmac, Nicolò Mezzina, Riccardo Patti, Danilo Licastro, Simeone Dal Monego, Cristiana Abazia, Luisa Petraccia, Flora Masutti, Saveria L. Crocè, Raffaella Calligaris, Claudio Tiribelli. Changes in circulating microRNA after treatment: microRNA signatures to predict therapy response and disease free survival in hepatocellular carcinoma patients. *UEG Journal* 2016 4(5S) A1–A156. Doi.org/10.1177/2050640616663688
- 2016 **D. Pascut**, P. Popović, C. Tiribelli. Adaptive mechanisms leading to multidrug resistance in Hepatocellular carcinoma. *J.Hepatology* 2016 Vol.64, S425-S630. doi.org/10.1016/S0168-8278(16)01016-3
- 2016 I.Martinozzi, N.Rosso, C.Tiribelli, **D.Pascut**. Molecular networks in hepatocellular carcinoma: the extratelomeric effects of telomerase. *J.Hepatology* 2016 Vol.64, S425-S630. doi.org/10.1016/S0168-8278(16)01015-1
- 2016 **Devis Pascut**, Helena Krmac, Nicolò Mezzina, Riccardo Patti, Danilo Licastro, Simeone Dal Monego, Cristiana Abazia, Luisa Petraccia, Flora Masutti, S L. Crocè, R.Calligaris, C. Tiribelli. Circulating microRNA in hepatocellular carcinoma as prognostic biomarkers. *Digestive and Liver Disease* 48S (2016) e18–e41. doi.org/10.1016/j.dld.2015.12.061
- 2016 I.Martinozzi, N.Rosso, C.Tiribelli, **D.Pascut**. The telomerase extratelomeric effects in HCC: Molecular targeting to impair tumoral networks in HCC. *Digestive and Liver Disease* 48S (2016) e18–e41. doi.org/10.1016/j.dld.2015.12.058
- 2016 P. Popović, C. Tiribelli, **D. Pascut**. The Role of mir-124 and Aurora kinase-A in the multidrug resistance in HCC. *Digestive and Liver Disease* 48S (2016) e1–e17. doi.org/10.1016/j.dld.2015.12.030
- 2015 **D. Pascut**, R. Patti, G. Bedogni C. Tiribelli. miRNA target enrichment network analysis in Hepatocellular carcinoma. *FEBS Journal*, 2015, Vol 282, Suppl.S1:56–248. doi.org/10.1111/febs.13339
- 2015 Sukowati CH, Anfuso B, **Pascut D**, Tiribelli C. Multidrug resistance in hepatic cancer stem cells: the emerging role of miRNAs. *Expert Rev Gastroenterol Hepatol*. 2015 Jun;9(6):723-5. doi: 10.1586/17474124.2015.1041509
- 2015 **Pascut D**, Bedogni G, Tiribelli C. Silencing efficacy prediction: a retrospective study on target mRNA features. *Biosci Rep*. 2015, 35(2). pii: e00185. Doi: 10.1042/BSR20140147.
- 2015 C. H.C. Sukowati, B. Anfuso, **D. Pascut**, R. Patti, N. Mezzina, P. Tarchi, S.L. Crocè, C. Tiribelli. Distribution of stem cells and cancer stem cells markers in liver pathologies and their indication to the response of therapy. *Digestive and Liver Disease* 47S (2015) e56. doi.org/10.1016/j.dld.2015.01.122
- 2015 R. Patti, N. Mezzina, F. Masutti, C. Abazia, V. Lanzillotti, **D. Pascut**, C. H.C. Sukowati, F. Pozzi Muceli, C. Tiribelli, S.L. Crocè. TACE with cone beam computed tomography is more effective than traditional technique in BCLC A HCC patients ineligible to surgery. *Digestive and Liver Disease* 47S (2015) e33. doi.org/10.1016/j.dld.2015.01.075.
- 2015 **D. Pascut**, R. Patti, N.Mezzina, C. Abazia, F. Masutti, S.L. Crocè, C. Tiribelli. Mir-106b for HCC Patient management after therapy. *Digestive and Liver Disease* 47S (2015) e24. doi.org/10.1016/j.dld.2015.01.055
- 2012 Sukowati CH, Rosso N, **Pascut D**, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. *BMC Gastroenterol*. 2012 Nov 15;12:160. doi: 10.1186/1471-230X-12-160.
- 2012 **Devis Pascut**, Natalia Rosso, Claudio Tiribelli. Targeting telomerase reverse transcriptase: A molecular approach for gene therapy in HCC. *FEBS Journal*, September 2012, Vol. 279, Issue Supplement s1 (341-342). doi.org/10.1111/j.1742-4658.2010.08705.x
- 2012 Rosso N, **Pascut D**, Crocè L, Tiribelli C. Development of Doxorubicin-resistance in HCC: in vitro molecular insights. *J.Hepatology*, April, 2012 Vol.56, Supplement 2, S125 (S71-S224). doi.org/10.1016/S0168-8278(12)60317-1
- 2011 N.Rosso, **D.Pascut**, C.Tiribelli. Molecular events in the Development of Doxorubicin-Resistant Hepatic Cell Lines. *The FEBS Journal*, Vol 278, Suppl.1 June 2011. P11.168
- 2009 **Pascut D**, Princi T, Donato M, Tamaro G, Parco S. “Antiphospholipid antibodies and lipoprotein(a) in obese children”. *Acta Paediatr*. 2009 Apr;98(4):703-7. doi: 10.1111/j.1651-2227.2008.01182.x
- 2007 Tamaro G., **Pascut D.**, Bevacqua G., Donato M. A. “Obesità infantile: difetto genetico o errato stile di vita?” (ORDINE NAZIONALE DEI BIOLOGI, La Biologia verso il futuro 2007) atti di: XX Congresso Internazionale ONB, Abano Terme (PD), 26-30 Settembre 2007 Vol 2pp 127 -161.

A handwritten signature in black ink, reading "Devis Pascut". The signature is written in a cursive style with a long horizontal line extending from the end of the name.